Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial
Our study suggests differential tamoxifen benefit by menopausal status. Improved long-term endocrine therapy prediction in premenopausal patients is needed and could involve molecular markers because standard tumor characteristics cannot predict benefit beyond 10 years.
Authors
- Linda S. Lindström (ORCID: https://orcid.org/0000-0002-7722-7532)
- Nicholas P. Tobin (ORCID: https://orcid.org/0000-0003-2343-9772)
- Bo Nordenskjöld (ORCID: https://orcid.org/0000-0002-2134-7586)
- Christopher C. Benz (ORCID: https://orcid.org/0000-0001-5479-4641)
- Laura van ‘t Veer (ORCID: https://orcid.org/0000-0002-9838-8298)
- Huma Dar (ORCID: https://orcid.org/0000-0003-0710-1448)
- Annelie Johansson (ORCID: https://orcid.org/0000-0001-9029-1996)
- Olle Stål (ORCID: https://orcid.org/0000-0002-8290-0592)
- Gizeh Pérez‐Tenorio
- Christina Yau (ORCID: https://orcid.org/0000-0002-1937-0859)
- Tommy� Fornander
- Laura J. Esserman (ORCID: https://orcid.org/0000-0001-9202-4568)
- Anna Nordenskjöld (ORCID: https://orcid.org/0000-0002-9123-4931)
Institutions
- Linköping University (SE)
- Karolinska University Hospital (SE)
- Buck Institute for Research on Aging (US)
- University of California, San Francisco (US)
- Karolinska Institutet (SE)
- Breast Center (CH)
- University of Gothenburg (SE)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1093/jnci/djae268
- Citations
- 2
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- California Breast Cancer Research Program
- Cancerfonden
- Vetenskapsrådet
- Forskningsrådet om Hälsa, Arbetsliv och Välfärd
- National Institutes of Health